Drug Profile
GT 103
Alternative Names: GT 103Latest Information Update: 05 Feb 2024
Price :
$50
*
At a glance
- Originator Duke University
- Developer Duke University; Grid Therapeutics; Merck Sharp & Dohme
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Complement factor H inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Non-small cell lung cancer
Most Recent Events
- 24 Jan 2024 Suspended - Phase-II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT05617313)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Recurrent, Second-line therapy or greater) in USA (IV)
- 02 Jun 2023 Efficacy and adverse events data from a phase Ib trial in Non-small cell lung cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)